Tarsus Pharmaceuticals annual stock-based compensation
2019
2020
2021
2022
2023
2024
2025
Tarsus Pharmaceuticals Stock-Based Compensation Growth & History (TARS)
Tarsus Pharmaceuticals's stock-based compensation was $41.7M for fiscal 2025.
View full Tarsus Pharmaceuticals company overviewTarsus Pharmaceuticals annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $41.7M | $13.9M | +49.97% |
| 2024 | 2024-12-31 | $27.8M | $8.0M | +40.28% |
| 2023 | 2023-12-31 | $19.8M | $6.4M | +47.33% |
| 2022 | 2022-12-31 | $13.5M | $5.0M | +59.20% |
| 2021 | 2021-12-31 | $8.5M | $7.6M | +907.75% |
| 2020 | 2020-12-31 | $839,000 | $821,000 | +4561.11% |
| 2019 | 2019-12-31 | $18,000 | — | — |
Tarsus Pharmaceuticals quarterly stock-based compensation
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $13.3M | $5.1M | +61.41% |
| Q1 2026 | 2026-03-31 | $12.0M | $5.0M | +72.68% |
| Q4 2025 | 2025-12-31 | $14.3M | $6.9M | +93.35% |
| Q3 2025 | 2025-09-30 | $12.2M | $4.8M | +65.11% |
| Q2 2025 | 2025-06-30 | $8.2M | $752,000 | +10.05% |
| Q1 2025 | 2025-03-31 | $6.9M | $1.4M | +25.57% |
| Q4 2024 | 2024-12-31 | $7.4M | $1.9M | +35.04% |
| Q3 2024 | 2024-09-30 | $7.4M | $2.2M | +41.24% |
| Q2 2024 | 2024-06-30 | $7.5M | $2.3M | +44.09% |
| Q1 2024 | 2024-03-31 | $5.5M | $1.6M | +41.30% |
| Q4 2023 | 2023-12-31 | $5.5M | $1.8M | +49.33% |
| Q3 2023 | 2023-09-30 | $5.3M | $1.7M | +46.53% |
| Q2 2023 | 2023-06-30 | $5.2M | $1.7M | +47.00% |
| Q1 2023 | 2023-03-31 | $3.9M | $1.2M | +46.07% |
| Q4 2022 | 2022-12-31 | $3.7M | $1.5M | +68.47% |
| Q3 2022 | 2022-09-30 | $3.6M | $1.5M | +69.09% |
| Q2 2022 | 2022-06-30 | $3.5M | $738,000 | +26.41% |
| Q1 2022 | 2022-03-31 | $2.7M | $1.3M | +96.18% |
| Q4 2021 | 2021-12-31 | $2.2M | $1.7M | +397.49% |
| Q3 2021 | 2021-09-30 | $2.1M | $1.9M | +845.98% |
| Q2 2021 | 2021-06-30 | $2.8M | $2.6M | +1515.03% |
| Q1 2021 | 2021-03-31 | $1.4M | $1.4M | +33975.00% |
| Q4 2020 | 2020-12-31 | $438,000 | — | — |
| Q3 2020 | 2020-09-30 | $224,000 | $219,000 | +4380.00% |
| Q2 2020 | 2020-06-30 | $173,000 | — | — |
| Q1 2020 | 2020-03-31 | $4,000 | — | — |
| Q3 2019 | 2019-09-30 | $5,000 | — | — |
Tarsus Pharmaceuticals stock-based compensation trends
Over the last five fiscal years, Tarsus Pharmaceuticals's stock-based compensation increased from $839,000 to $41.7M, a change of $40.9M. The latest reported quarter, Q2 2026, shows $13.3M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tarsus Pharmaceuticals source filings ↗